clinical trial – Page 8

Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial

By MedXY 08/08/2025

A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.

Clinical Updates Diabetes & Endocrinology news Respiratory Specialties

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

By MedXY 08/08/2025

Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.

Clinical Updates Neurology news Pediatrics Specialties

Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?

By MedXY 08/08/2025

A phase II trial finds that intrathecal autologous bone marrow mononuclear cell therapy combined with education significantly improves core symptoms and adaptive behaviors in young children with ASD compared to education alone.

$Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial$

Clinical Updates Hematology-Oncology news Specialties

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

By MedXY 08/07/2025

The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.

Clinical Updates Hematology-Oncology news Specialties

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By MedXY 08/07/2025

A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.

Clinical Updates General Surgery news Oncology Radiology Specialties

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Clinical Updates news Oncology Specialties

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Clinical Updates General Surgery news Oncology Specialties

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Hematology-Oncology news Specialties Transplantation

Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial

By MedXY 08/07/2025

A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this population.

Clinical Updates news Specialties Urology

Testosterone Therapy in Middle-Aged and Older Men with Hypogonadism: Balancing Clinical Benefits and Risks

By MedXY 08/07/2025

Testosterone therapy offers modest benefits for sexual function, anemia, and bone health in older men with hypogonadism, but increases risks of venous thromboembolism, fractures, and arrhythmias. Careful patient selection and individualized risk-benefit assessment are essential.

Clinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY 08/05/2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.

Clinical Updates Diabetes & Endocrinology news Specialties

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY 08/05/2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Clinical Updates Neurology news Specialties

Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial

By MedXY 08/03/2025

Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.

Clinical Updates news

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

By MedXY 08/03/2025

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.

Clinical Updates news Rheumatology Specialties

Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy

By MedXY 08/03/2025

A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

By MedXY 08/03/2025

Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.

Clinical Updates news Oncology Specialties

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

By MedXY 08/03/2025

Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.